Search

Your search keyword '"Grever, Michael R,"' showing total 338 results

Search Constraints

Start Over You searched for: Author "Grever, Michael R," Remove constraint Author: "Grever, Michael R," Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
338 results on '"Grever, Michael R,"'

Search Results

7. The long noncoding RNA, treRNA, decreases DNA damage and is associated with poor response to chemotherapy in chronic lymphocytic leukemia

10. Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients

11. Final results of EFC6663: A multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia

13. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia

24. Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study

25. FISH Analysis of CDKN2A/B Deletion in Chronic Lymphocytic Leukemia

26. Retrospective Analysis of Residual Hairy Cell Leukemia Measured By IHC or Flow Cytometry and Frontline Treatment with Pentostatin on Time to Next Treatment

27. Treatment of CLL-Associated Autoimmune Cytopenias and Outcomes in a Single Institution Cohort Study

28. Incidence, Description, and Timing of Serious or Opportunistic Infections in Patients with Hairy Cell Leukemia Treated with Purine Nucleoside Analogues

29. Characterizing the Development of Secondary Myelodysplastic Syndrome (MDS) with Antecedent or Concurrent Chronic Lymphocytic Leukemia (CLL) in the Era of Small Molecule Inhibitors for the Treatment of CLL

30. Extended Follow up of a Phase 2 Study of Ibrutinib in Hairy Cell Leukemia

31. Patient characteristics that predict Richter's transformation in patients with chronic lymphocytic leukemia treated with ibrutinib

34. Impact of sex on outcomes in patients with hairy cell leukemia (HCL): An HCL Patient Data Registry (PDR) analysis.

41. Normal FISH CLL Represents a Heterogeneous Subgroup Where Prognosis Can be Refined with IGHV Mutational Status

42. Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia

43. Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL)

44. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia

45. Phase 2 study of ibrutinib in classic and variant hairy cell leukemia

49. DNA Methylation-Based Classification of Hairy Cell Leukemia and Splenic B Cell Lymphoma

Catalog

Books, media, physical & digital resources